Abstract
AbstractGram-negative bacteria cause the majority of critically drug-resistant infections, necessitating the rapid development of new drugs with Gram-negative activity. However, drug design is hampered by the low permeability of the Gram-negative cell envelope and the function of drug efflux pumps, which extrude foreign molecules from the cell. A better understanding of the molecular determinants of compound recognition by efflux pumps is, therefore, essential. Here, we quantitatively analysed the activity of 73,737 compounds, recorded in the publicly accessible database CO-ADD, across three strains of E. coli – the wild-type, the efflux-deficient tolC variant, and the hyper-permeable lpxC variant, to elucidate the molecular principles of evading efflux pumps. We computationally investigated molecular features within this dataset that promote, or reduce, the propensity of being recognised by the TolC-dependent efflux systems in E. coli. Our results show that, alongside a range of physicochemical features, the presence or absence of specific chemical groups in the compounds substantially increases the probability of avoiding efflux. A comparison of our findings with inward permeability data further underscores the primary role of efflux in determining drug bioactivity in Gram-negative bacteria.
Publisher
Springer Science and Business Media LLC
Reference57 articles.
1. Shrivastava, S. R., Shrivastava, P. S. & Ramasamy, J. World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. JMS - J. Med. Soc. 32, 76–77 (2018).
2. World Health Organization (WHO). 2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline (WHO, Geneva, 2019).
3. WHO Antimicrobial Resistance Division Global Coordination and Partnership. 2020 Antibacterial Agents in Clinical and Preclinical Development (WHO, Geneva, 2021).
4. Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318–327 (2018).
5. World Health Organization. 2021 antibacterial agents in clinical and preclinical development: an overview and analysis (WHO, Geneva, 2022).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献